OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.

@article{Kraus2015OARSICT,
  title={OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.},
  author={Virginia B. Kraus and Francisco J Blanco and Martin Englund and Yves Edgard Henrotin and L Stefan Lohmander and Elena Losina and Patrik {\"O}nnerfjord and Stefano Persiani},
  journal={Osteoarthritis and cartilage},
  year={2015},
  volume={23 5},
  pages={686-97}
}
The objective of this work was to describe requirements for inclusion of soluble biomarkers in osteoarthritis (OA) clinical trials and progress toward OA-related biomarker qualification. The Guidelines for Biomarkers Working Group, representing experts in the field of OA biomarker research from both academia and industry, convened to discuss issues related to soluble biomarkers and to make recommendations for their use in OA clinical trials based on current knowledge and anticipated benefits… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
21 Citations
60 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 60 references

Micheel C, Ball J, Eds

  • Institute of Medicine. Evaluation of biomarkers, surrogate endpoints in chronic disease. In
  • Brief V.B. Kraus et al. / Osteoarthritis and…
  • 2015

Classi fi cation of osteoarthritis biomarkers : a proposed approach

  • DC Bauer, DJ Hunter, SB Abramson, M Attur, M Corr, D Felson
  • Ann Rheum Dis
  • 2014

Guidance for Industry: Expedited Programs for Serious Conditions e Drugs and Biologics

  • FDA, CDER, CBER
  • 2014

Similar Papers

Loading similar papers…